Osiris Therapeutics, Inc. (OSIR)
-NasdaqGM 10.65 
0.37(3.60%) Jun 18, 4:00PM EDT
| Prev Close: | 10.28 |
|---|
| Open: | 10.27 |
|---|
| Bid: | 9.99 x 100 |
|---|
| Ask: | 11.49 x 200 |
|---|
| 1y Target Est: | 8.50 |
|---|
| Beta: | 1.73 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 10.13 - 10.89 |
|---|
| 52wk Range: | 6.55 - 14.46 |
|---|
| Volume: | 245,988 |
|---|
| Avg Vol (3m): | 113,259 |
|---|
| Market Cap: | 350.72M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Osiris - Can Stem Cells Lead To Profits?at Seeking Alpha(Mon, Jun 17)
- Penny-Wise, Pound-Foolish Stem Cell Stocksat Seeking Alpha(Fri, Jun 14)
- OSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Sun, Jun 2)
- Osiris Therapeutics to Present at the Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Thu, May 30)
- OSIRIS THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Pipeline Progress at GileadZacks(Thu, May 16)
- OSIRIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Is the Golden Age of Blockbusters Over?at Motley Fool(Thu, May 9)
- Osiris Loss In-Line with ExpectationsZacks(Wed, May 8)
- Safe Stem Cell Therapy for Healing Is Still a Strong Betat Motley Fool(Tue, May 7)
- Osiris Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Osiris Therapeutics price target raised to $14 from $11.50 at Piper Jaffraytheflyonthewall.com(Tue, May 7)
- Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Usedat TheStreet(Tue, May 7)
- Osiris Therapeutics Announces First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 7)
- Q1 2013 OSIRIS THERAPEUTICS INC Earnings Release - Before Market OpenCCBN(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 29.54 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.31 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 3.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets.
View More